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Abstract
White matter (WM) abnormalities are frequently seen on brain MRI of HIV positive (HIV+ ) patients. We aimed
to determine the prevalence of unexplained WM abnormalities and their associations with HIV disease and
cardiovascular risk factors. We conducted a retrospective, cross-sectional study of brain MRI of HIV+ patients
conducted between 2004 and 2009 at our center. Clinical and laboratory data were compiled, and images were
independently reviewed for WM lesions. Images were obtained from 254 patients: 70% male, 53% white, 40%
black, mean age 42 years, median current CD4 count 240 cells/mm3, and 41% not taking antiretroviral therapy
(ART). Hyperintense WM lesions were present in 161 patients (63.4%): 89 scans (35.0%) showed diffuse WM
signal abnormality (DWMSA), 61 (24.0%) were consistent with small vessel disease (SVD, graded by Fazekas’
scale), and 37 (14.6%) showed large asymmetrical focal WM lesions. SVD changes were associated with age and
cardiovascular risk factors, and while cerebral SVD may be related to HIV infection, the MRI findings were not
associated with HIV-related factors. The only risk factor for DWMSA was black race, and no correlation with
cardiovascular risk factors, CD4 count, or clinical presentation was identified. DWMSA are therefore of un-
certain neurological significance in HIV+ patients and could represent more than one clinicopathological entity.
Introduction
The clinical and radiological spectrum of centralnervous system (CNS) disease in HIV positive (HIV + )
patients has evolved since highly-active antiretroviral therapy
(HAART) was introduced in 1996, in that the incidence of
serious AIDS-defining CNS disease has decreased in coun-
tries with good access to HAART,1,2 but the prevalence of
milder neurocognitive impairment (NCI) in individuals living
with HIV has increased and is estimated at 19–69%.3–7
Recent neuroimaging studies have used advanced magnetic
resonance imaging (MRI) techniques such as diffusion-
weighted (DWI) and diffusion tensor imaging (DTI),8–10
volumetric analysis 11,12 and arterial spin labeling13 to explore
biomarkers of HIV infection and of NCI in HIV+ patients. In
particular, research using diffusion-based techniques suggests
that HIV infection and HIV-associated NCI are associated
with increased diffusivity and reduced anisotropy in cerebral
white matter (WM).8,14 However, there have been few studies
using standard clinical diagnostic MRI techniques in recent
years. Although early work found little evidence for a dif-
ference between the prevalence of focal WM abnormalities in
HIV+ patients and seronegative controls,15–17 considerable
changes have occurred since the 1980s in clinical HIV med-
icine and MR radiography. Hyperintense WM lesions are
often seen in the normal aging population, with a strong as-
sociation with cerebrovascular disease,18–20 though their
pathogenesis is not well understood and may be multifacto-
rial.21 Their significance in HIV clinical practice, particu-
larly as an incidental finding, remains unclear. There have
been recent advances in non-imaging tools used to diagnose
and monitor NCI in HIV,22–25 using techniques that are re-
producible and require less expertise than neuropsychologi-
cal assessment. However, given some of the uncertainty over
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the longer term clinical importance of mild-to-moderate
cognitive difficulties, improved understanding of biomarkers
such as structural and functional imaging is vital.
Our main aim was to estimate the prevalence of WM ab-
normalities, subdivided according to morphology, in patients
undergoing brain MRI for clinical reasons. Our second aim
was to determine whether unexplained WM lesions (UWML)
of different distributions were associated with HIV-related
factors (such as degree of immunodeficiency, and ART sta-
tus) or with cardiovascular risk factors.
Methods
Patient sampling and magnetic resonance imaging
We conducted a retrospective, cross-sectional study in an
observational clinical setting. All HIV+ patients undergoing
in- or outpatient brain MRI for clinical indications between
April 2004 and November 2009 at a single tertiary hospital in
London, UK, were identified. MRI was performed at 1.5 Tesla
using a standardized clinical protocol that included T1- and
T2-weighted and fluid-attenuated inversion recovery (FLAIR)
imaging, with gadolinium enhancement where clinically ap-
propriate. In patients who had had multiple scans during the
sampling period, only the earliest available scan was included.
The presence or absence of cerebral WM abnormalities,
appearing hyperintense on T2-weighted and FLAIR imaging,
was first reported by one of two study radiologists (CD and
HC), who were blinded to the original clinical presentation
and subsequent progress and investigations. Standardization
of the classification method between raters was provided by
training in the use of the Fazekas Scale, an established and
validated method of reporting WM hyperintensities of pre-
sumed vascular origin from a single MRI,26 from two expe-
rienced neuroradiologists (HRJ and HH). Validation checks
included the re-reporting of 35% of the images (randomly
selected by computer) by a single radiologist (HC), again
blinded to clinical details and the results of the earlier review.
The classifications of the remainder were compared with the
original clinical report. Any differences between classifica-
tions were adjudicated by the lead investigator (HRJ).
WM abnormalities were classified as focal or diffuse. Focal
lesions consistent with cerebrovascular small vessel disease
(SVD) were graded according to the Fazekas scale, which
classifies SVD into four broad categories (0, no WM lesions; 1,
small punctate lesions only; 2, early confluent lesions; 3,
confluent WM lesions) and takes into account the number of
small WM hyperintensities expected for age. The second type
of focal WM hyperintensity was large asymmetrical lesions,
presumed not of vascular origin. Diffuse white matter signal
abnormality (DWMSA) was graded qualitatively as ‘‘intense’’
if with the signal was more intense than gray matter on T2-
weighted and FLAIR images, or ‘‘subtle’’ if the signal on T2-
weighted and FLAIR images was iso- or hypointense relative
to gray matter. Leptomeningeal enhancement, parenchymal
enhancement, mass effect and atrophy were also recorded.
Patients without gradable MR scans, because of missing se-
quences or severe movement artefact, were excluded.
Clinical data collection
Clinical and laboratory data were compiled and reviewed
by a different investigator (LJH). Patients with WM abnor-
malities were then categorized into those with a definitive,
explanatory diagnosis, and those with no explanatory con-
dition identified, based on clinical and laboratory findings
close to the date of the MR scan. A diagnosis of HIV en-
cephalopathy, SVD, or viral encephalitis that was made on
clinical or radiological grounds after exclusion of other de-
finitive diagnoses but not confirmed by virological or histo-
pathological evidence was not considered to be definitive or
explanatory. Patients in the second group (no explanatory
condition) were deemed to have UWML. The remaining
patients did not have any WM abnormalities visible on
standard brain MRI.
Additional data collected included markers of immuno-
deficiency [current and nadir CD4 + lymphocyte count,
current antiretroviral therapy (ART), duration of treatment
with ART, HIV-1 viral load (VL), duration of HIV infection]
and cardiovascular risk factors (current and previous ciga-
rette smoking, diabetes mellitus, hyperlipidaemia, systemic
hypertension, age, sex, previous cardiovascular events, co-
caine use). Long-term follow-up data was obtained from case
note review, to determine subsequent worsening or emer-
gence of cognitive, motor, or behavioral symptoms.
Statistical analysis
After compiling descriptive clinical and radiological sta-
tistics, patients with WM lesions with a definitive, explana-
tory clinical or microbiological diagnosis were excluded
from further analysis. In the remaining patients, those with
SVD-type UWML were compared to those without such le-
sions, using Mantel-Haenszel methods to calculate odds ra-
tios (OR) and 95% confidence intervals (CI). Variables were
divided into cardiovascular risk factors (e.g., age, sex, dia-
betes, hypertension, cigarette smoking) and HIV-related
factors (e.g., current and nadir CD4 count, treatment status,
duration of infection). Where large numbers of patients had
missing data (e.g., cigarette smoking status), ‘‘missing’’ was
treated as a separate category in the analysis. Adjusted OR
were then calculated using a multivariable logistic regression
model incorporating all variables with p < 0.10 in the uni-
variate analysis. Statistical significance of the final results
was defined by a p value of < 0.05. A similar analysis was
conducted for factors associated with unexplained DWMSA.
The longer-term implications of unexplained intense
DWMSA were explored by (1) calculating rates of incidence
of new or worsening cognitive, motor, or behavioral symp-
toms, and (2) qualitatively reviewing the clinical histories of
patients with this neuroimaging abnormality.
Sample size was determined pragmatically according to
available data, as the study was primarily a prevalence study.
All statistical calculations were carried out using STATA
SE12 software (StataCorp, Texas, USA).
Ethics approval
The Chairman of the Local Research Ethics Committee
(LREC) (National Research Ethics Service Committee
London–Camden and Islington) determined that this project
did not require LREC approval as all data used in the present
study were accrued from patients who were undergoing
routine, clinically indicated investigations, and no informa-
tion was collected that was not available in clinical records.
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Results
Demographic and clinical characteristics
During the study period, 254 HIV+ individuals underwent
brain MRI and had complete, gradable images. The main
characteristics of these patients are shown in Table 1. Cardio-
vascular risk factors (not tabulated) were as follows: 98
(38.6%) current or ex-smokers, 95 (37.4%) non-smokers; 15
(5.9%) diabetic; 60 (23.6%) hyperlipidemia; 40 (15.7%) sys-
temic hypertension, 183 (72.0%) normotensive; 32 (12.6%)
cocaine users, 85 (33.5%) did not use cocaine; 29 (11.4%) with
previous cardiovascular disease. Cardiovascular variables were
frequently missing from the notes: 61 (24.0%) smoking status
not recorded, 31 (12.1%) presence or absence of systemic hy-
pertension not available; 137 (53.9%) cocaine use not recorded.
The clinical indications for brain MRI were focal neuro-
logical symptoms or signs (n= 63, 24.8%), complicated
headache (severe in intensity, or associated with other neu-
rological symptoms or fever) (n = 42, 16.5%), chronic or
subacute symptoms of cognitive impairment (n= 33, 13.0%),
multi-system illness (n = 33, 13.0%), acute confusion or be-
havioral change (n = 32, 12.6%), seizures or blackouts
(n= 26, 10.2%), and chronic uncomplicated headaches (23,
9.1%). The indication could not be determined from available
clinical records in 2 patients. Of the 254 patients, 113 (44.5%)
had lumbar puncture during the same clinical episode as the
brain MRI. Cerebrospinal fluid (CSF) HIV VL was measured
in 38 (33.6%) of those undergoing lumbar puncture and 21
had detectable ( > 50 copies/mL) CSF VL, although only 2 of
the 21 patients had a concurrent undetectable plasma VL.
Prevalence of WM abnormalities,
and associated clinical and imaging findings
Overall, 161 scans (63.4%) showed WM abnormalities
(Table 2). These included: DWMSA in 89 scans (35.0%),
Table 1. Age, Sex and HIV-Related Characteristics
of Study Patients (n = 254)
Median (IQR) Number (%)
Age 42.2 (35.9–48.3)
Male 178 (70.1)
Ethnic group
White 134 (52.8)
Black 102 (40.2)
Other/mixed 18 (7.1)
Route of infection
Heterosexual 117 (46.1)
MSM 108 (42.5)
Vertical 7 (2.8)
IVDU/other/not known 22 (8.7)
Nadir CD4 100 (40–210)
Current CD4 240 (100–440)
Current treatment statusa
Suppressed on ART 94 (37.0)
Early treatment 25 (9.8)
Failed treatment 28 (11.0)
Off ART 104 (40.9)
Not known 3 (1.2)
Years since diagnosis
of HIV
4.6 (0.6–11.0)
Total duration
of ART in years
3.8 (1.1–8.0)
aSuppressed on ART =HIV-1 viral load (VL) less than 50 copies/
mL; early treatment =VL greater than 50 copies/mL but duration of
antiretroviral therapy (ART) less than 3 months; failed treat-
ment =VL greater than 50 copies/mL and duration of ART greater
than 3 months.
ART, antiretroviral therapy; IQR, inter-quartile range; IVDU,
intravenous drug user; MSM, men who have sex with men.
Table 2. Summary of Abnormalities Detected in Scans of HIV + Patients Undergoing
Brain Magnetic Resonance Imaging (n = 254)
Patients with WM
abnormalities
with explanatory
diagnosis, n (%)
Patients with
unexplained WM
abnormalities,
n (%)
Patients
with no WM
abnormalities,
n (%) Total, n (%)
Number of patients 66 (26.0) 95 (37.4) 93 (36.6) 254 (100)
Diffuse WM signal abnormality
Subtle 4 (1.6) 51 (20.1) 0 55 (21.7)
Intense 21 (8.3) 13 (5.1) 0 34 (13.4)
Any 25 (9.8) 64 (25.2) 0 89 (35.0)
Focal WML (SVD)
Fazekas grade 1 15 (5.9) 32 (12.6) 0 47 (18.5)
Fazekas grade 2 2 (0.8) 9 (3.5) 0 11 (4.3)
Fazekas grade 3 1 (0.4) 2 (0.8) 0 3 (1.2)
Any grade of SVD 18 (7.1) 43 (16.9) 0 61 (24.0)
Large, focal WML (non-SVD) 32 (12.6) 5 (2.0) 0 37 (14.6)
Cerebral atrophy 26 (10.2) 38 (15.0) 19 (7.5) 83 (32.7)
Meningeal enhancement 8 (3.1) 4 (1.6) 3 (1.2) 15 (5.9)
Mass lesion
Single 3 (1.2) 4 (1.6) 7 (2.8) 14 (5.5)
Multiple 14 (5.5) 2 (0.8) 7 (2.8) 23 (9.1)
Percentages are expressed as a proportion of the entire study sample.
SVD, small vessel disease; WM, white matter; WML, white matter lesions.
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Table 3. Analysis of Associations Between Exposure Variables and Small Vessel Disease-Type Lesions
(Fazekas Grade 1–3), After Exclusion of Patients with Explained White Matter Lesions (n = 192)
Crude odds ratio
(95% CI) p Value
Adjusted odds
ratioa (95% CI) p Value
Demographic variables
Age
< 35 years 1.0
35–50 years 4.39 (1.22–15.8) 0.014
> 50 years 8.32 (1.92–36.0) 0.0007
Per+ 1 year 1.05 (1.01–1.09) 0.007 1.05 (1.01–1.09) 0.012
Male 1.0
Female 1.79 (0.86–3.73) 0.11
Ethnicity
White 1.0
Black 1.70 (0.83–3.49) 0.14
Other/mixed 1.28 (0.32–5.10) 0.73
Route of infection or risk group
Heterosexual 1.0 2.22 (1.04–4.71) 0.038
MSM 0.55 (0.26–1.15) 0.10 (Heterosexual
Vertical 0.49 (0.05–4.48) 0.52 vs. other routes)
IVDU/other 0.56 (0.14–2.19) 0.40
Immunodeficiency and HIV-related variables
Nadir CD4 count
> 350 cells/mm3 1.0
200–350 cells/mm3 0.62 (0.15–2.61) 0.51
< 200 cells/mm3 0.56 (0.15–1.99) 0.36
Current CD4 count
> 350 cells/mm3 1.0
200–350 cells/mm3 1.23 (0.50–3.03) 0.65
< 200 cells/mm3 0.95 (0.43–2.09) 0.90
Change in CD4 count relative to nadir
Current= nadir 1.0
Increased 1–100 cells/mm3 1.08 (0.43–2.70) 0.87
Increased 100–250 cells/mm3 1.23 (0.45–3.36) 0.69
Increased > 250 cells/mm3 0.83 (0.32–2.15) 0.71
Suppressed on ARTb 1.0
Early treatmentb 0.84 (0.24–2.91) 0.78
Failed treatmentb 1.26 (0.42–3.80) 0.68
Off ART 0.65 (0.30–1.45) 0.29
Not known 2.94 (0.17–51.1) 0.44
Time since diagnosis of HIV
< 1 year 1.0
1–5 years 1.65 (0.64–4.26) 0.29
> 5 years 1.02 (0.43–2.40) 0.97
Total duration of treatment
Never treated 1.0
< 1 year 1.15 (0.39–3.38) 0.80
1–5 years 1.50 (0.60–3.71) 0.38
> 5 years 1.45 (0.59–3.58) 0.42
Not known 4.21 (0.24–74.6) 0.29
Cardiovascular risk factors
Cigarette smoking status
Non-smoker 1.0
Ex- or current smoker 0.64 (0.28–1.43) 0.27
Not available 0.94 (0.40–2.21) 0.90
Nondiabetic 1.0
Diabetic 4.64 (1.16–18.6) 0.017 3.17 (0.74–13.6) 0.12
Normal lipids 1.0
Hyperlipidemia ( + /- treatment) 1.59 (0.74–3.43) 0.23
(continued)
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72% of which were unexplained, and 62% of which were
only subtly hyperintense; focal WM lesions consistent
with small vessel disease in 61 scans (24.0%), again mostly
(62%) without definite explanatory diagnoses; and large,
focal lesions in 37 scans (14.6%), most of which (86%)
were in association with a definitive intracranial pathology.
The most common diagnoses associated with large, focal
lesions in WM were progressive multifocal leucoencepha-
lopathy (PML; 14 cases), toxoplasmosis (8 cases), herpes-
virus meningoencephalitis (8 cases), and tuberculosis (6
cases).
Cerebral atrophy was more commonly observed in patients
with UWML than those without WM abnormalities. Eight
out of thirteen patients (61.5%) with intense DWMSA and
16/51 patients (31.4%) with subtle DWMSA had cerebral
atrophy compared to 33/124 (26.6%) without DWMSA
( p = 0.03). Similarly, 6/11 patients (54.5%) with Fazekas
grade 2–3 and 15/32 (46.9%) with Fazekas grade 1 had at-
rophy compared to 36/145 (24.8%) without SVD ( p = 0.002).
There was no association between large, non-SVD focal WM
lesions and cerebral atrophy.
Factors associated with focal WM lesions
The remaining analyses included only those with UWML
(n = 95) and those with no WM abnormalities (n = 93). The
first analysis explored which variables were most strongly
associated with the presence of unexplained, focal WM le-
sions consistent with SVD in this sample of HIV + patients
(Table 3). This showed that age, previous cardiovascular
disease (CVD), diabetes, systemic hypertension, and to a
lesser extent heterosexual transmission, were associated
with the presence of WM lesions of presumed vascular or-
igin, although only age, route of transmission, and previous
CVD remained statistically significant when these five
variables were included in a multivariable logistic regres-
sion model. There was no association with current or nadir
CD4 count, treatment status or duration, or time since HIV
diagnosis.
Factors associated with unexplained diffuse white
matter signal abnormality
The factors associated with unexplained DWMSA, whe-
ther subtle or intense, were then assessed. This analysis (not
tabulated) showed that while age and cardiovascular risk
factors were not associated with DWMSA, there was an as-
sociation with black African race (OR 2.21, 95% CI 1.15–
4.22, p = 0.014) and heterosexual transmission (OR 2.19,
95% CI 1.17–4.11, p= 0.012). Heterosexual transmission and
black race were correlated with one another in this patient
population, and this colinearity led to the disappearance of a
statistical association of either variable with DWMSA when
both variables were included in the same logistic regression
model.
The clinical histories of the 13 patients with unexplained
DWMSA of high signal intensity (as opposed to subtle) were
reviewed in detail (Table 4). The clinical observations
demonstrated that most patients had concurrent imaging
findings and significant presenting histories, and that a pu-
tative diagnosis was usually assigned but often unconfirmed.
Six of the 13 patients (46%) had a clinical diagnosis of HIV
encephalopathy, but in most cases the MRI appearances were
the only supportive evidence, and there was no association
between DWMSA and chronic cognitive symptoms as the
primary presenting complaint. Eight (62%) of these patients
were of black African race, the remainder being white. Most
had no new significant neurological symptoms during follow-
up, although two patients went on to develop fluctuating
neurological symptoms and signs over a period of years, and
one developed significant cognitive impairment some years
later. This patient was diagnosed with neurosyphilis at the
time of brain MRI, a condition not typically associated with
neuroimaging findings of this kind.27 Of those with complete
subsequent records, those with unexplained intense DWMSA
did not experience new or worsening symptoms affecting
cognition, behavior, or movement at a greater rate than those
with no WM abnormalities ( p= 0.93) or those with subtle
DWMSA ( p = 0.63).
Discussion
In this study we found that 62% of HIV + patients un-
dergoing brain MRI had WM abnormalities using standard
imaging techniques in a clinical setting. The most common
abnormality was diffuse white matter signal abnormality,
mostly subtle in intensity and unexplained after further in-
vestigation. White matter hyperintensities of presumed vas-
cular origin21 were also commonly seen. Our findings are
important given the paucity of published data on cerebral
small vessel disease in HIV,28,29 the growing proportion of
older adults with HIV in many regions, and the frequent
difficulties encountered when interpreting the clinical and
Table 3. (Continued)
Crude odds ratio
(95% CI) p Value
Adjusted odds
ratioa (95% CI) p Value
Systemic hypertension
No 1.0
Yes ( + / - treatment) 2.69 (1.14–6.36) 0.019 1.39 (0.54–3.54) 0.49
Not available 0.90 (0.28–2.88) 0.85
No previous CVD 1.0
Previous CVD 3.36 (1.31–8.62) 0.0074 3.64 (1.32–10.07) 0.013
aThe adjusted model included all variables that were statistically significant to a p value of < 0.10 in univariate analyses.
bSuppressed on ART=HIV-1 viral load (VL) less than 50 copies/mL; early treatment=VL greater than 50 copies/mL but duration of
antiretroviral therapy (ART) less than 3 months; failed treatment=VL greater than 50 copies/mL and duration of ART greater than 3 months.
ART, antiretroviral therapy; CI, confidence interval; CVD, cardiovascular disease; IVDU, intravenous drug user; MSM, men who have
sex with men.
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pathological importance of subtle or unexplained WM le-
sions in HIV + patients. Although we did not directly com-
pare the patients in this study period with a pre-1996 study
sample, the proportion of patients with an opportunistic in-
fection was generally low (24%) and a high proportion (59%)
had no specific neurological diagnosis. In comparison to our
more recent data, a study published in 1995 reported that
scans from 188 consecutive untreated HIV + patients in
Germany commonly identified toxoplasmosis (25%), HIV
encephalopathy (10%), and PML (5%).30
SVD-type WM lesions were associated with typical ce-
rebrovascular risk factors such as age, diabetes, other CVD,
and hypertension. The strong association with age was no-
table particularly as the age of the patient had already been
taken into consideration when classifying SVD lesions, in
that scans were graded as normal if the number of lesions
seen was typical for the patient’s age. There was an asso-
ciation between route of HIV infection and SVD (hetero-
sexual patients had higher odds of having SVD). This could
be explained by ethnic and gender differences between risk
categories in UK HIV + patients translating to differences
in cardiovascular health. By contrast, diffuse signal hyper-
intensity was not associated with cardiovascular risk factors,
the only positive finding being an association with black
race. There was only a weak trend towards subsequent
neurocognitive symptoms. Large focal lesions (not typical
of small vessel disease) were typically seen in association
with inflammatory or space-occupying intracranial pathol-
ogy. After excluding scans with an explanatory diagnosis,
HIV-related factors such as receipt of ART, current and
nadir CD4 count, duration of infection and duration of
ART, were not associated with WM abnormalities of any
distribution.
Limitations of the study include its retrospective design
and the high likelihood of selection bias due to this being a
study of normal clinical practice. Another important limita-
tion is the use of qualitative neuroradiological classification.
While we believe that our use of the Fazekas scale—a
methodology that is well-established in the neuroradiological
literature for grading cerebral SVD—included sufficient va-
lidity checks to reach a high level of accuracy, we accept that
some random or systematic error could have occurred. Also,
the classification of ‘‘diffuse’’ versus ‘‘intense’’ WM lesions
may be somewhat subjective as quantitative analysis of sig-
nal intensity was not done in this study. Bearing this in mind
while interpreting our findings relating to DWMSA, we feel
that our classification represents the descriptive findings that
may arise in the course of clinical practice. Additionally, data
were incomplete in several areas: only a minority of patients
had lumbar puncture, and even fewer had measurement of
CSF HIV viral load, making complete correlation between
imaging and CSF abnormalities impossible. Sampling of the
CSF for measurement of viral nucleic acid titers is now
generally recommended in HIV + patients with neurological
or cognitive complaints31 and has become standard practice
at our center since the period of this study. Also, cardiovas-
cular risk data were often missing—particularly smoking
status—and more likely to have been recorded in those per-
ceived to be at higher risk (e.g., older men). In analysis, the
study lacked an HIV-negative or an asymptomatic HIV +
control group, so we could not determine whether HIV status
was independently associated with UWML, nor if the lesions
were caused by premature or accelerated aging in HIV +
patients. Also in the analysis, as numbers of patients within
particular subgroups were small, it was difficult to determine
the prognostic importance of unexplained WM lesions in
HIV.
Using routine clinical data from within the last decade, this
study echoes the findings from studies performed in the
1980s, prior to the availability of HAART and using MR
scanners of lower field strengths.15–17 In these earlier de-
scriptions, WM lesions were no more frequent or progressive
in HIV + men than in HIV-negative controls. There have
since been numerous small cross-sectional studies using ad-
vanced techniques such as DWI and DTI, which have pro-
vided further evidence for WM abnormalities as correlates of
both HIV infection and of HIV-associated neurocognitive
impairment. There is a lack of data from prospective longi-
tudinal and clinical studies in order to translate those findings
into clinical practice, but it may be that diffusion-based
techniques are required to be able to fully interpret the sig-
nificance of DWMSA in patients who have had other diag-
noses excluded.
It is likely that focal hyperintense WM lesions in HIV +
patients undergoing neuroimaging are very similar in nature
to the WM changes seen in normal aging and, more exten-
sively, in patients with small vessel disease. If it is assumed
that such lesions are vascular in origin, their presence in
HIV + patients requires them to be treated similarly to the
general population, in whom there is likely to be an associ-
ation with future cerebrovascular events, vascular dementia
and frailty.19,20,32–36 It is possible that HIV + patients expe-
rience accelerated cerebrovascular aging or faster progression
of SVD, but there are few imaging studies of cerebrovascular
disease in the HIV+ population, and none published to date
with an HIV-seronegative control group. The Hawaii Aging
with HIV Cohort has produced the only published work on
cerebral small vessel disease to date and describes a 48%
prevalence of moderate WM disease among HIV+ patients
without neurological disease,29 with a strong association with
age and a modest association with hypertension.28,29 The as-
sociation between NCI and cerebrovascular risk factors in
HIV+ patients37,38 and the similarity between the domains
affected in vascular dementia and HIV-associated neurocog-
nitive disorders35,38–40 raise the intriguing possibility that NCI
in HIV is in some way vascular in etiology. Previous work has
established the high burden of large-vessel atherosclerotic
disease in HIV, including ischemic stroke,41–44 subclinical
endothelial dysfunction, and increased carotid intima-media
thickness,45 femoral and carotid artery plaques detectable on
ultrasound,46 and coronary artery disease.43 The growing
proportion of older HIV+ patients47 makes small- and large-
vessel cerebrovascular disease an important area for the
clinical research agenda in future.
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